http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Apr 2026 15:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Press+Releases/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html <p class="bwalignc"> <i>Preliminary results suggest potential to support extended preservation time and donor heart utilization</i> </p> <p> TORONTO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xvivogroup.com%2F&amp;esheet=54520689&amp;newsitemid=20260422965497&amp;lan=en-US&amp;anchor=XVIVO&amp;index=1&amp;md5=85a641f2c8c5944f1a16f4f564053bb5" shape="rect">XVIVO</a>, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to http://www.streetinsider.com/Business+Wire/Late-Breaking+Data+from+PRESERVE+Trial+Evaluates+XVIVO%E2%80%99s+HOPE+Preservation+Approach+in+Heart+Transplantation/26350714.html Wed, 22 Apr 2026 15:00:00 -0400 A.06822034 A.08652595 A.31910909 O.00620980 O.00628087 O.00782611 O.20026344 XVIPY XVIVO